A prospective study of steroid maintenance therapy in angioimmunoblastic T cell lymphoma

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: Following 1st course of CHOP therapy, PSL 0.5mg/kg/day was initiated from day 6 as maintenance therapy CONDITION: Angioimmunoblastic T cell lymphoma PRIMARY OUTCOME: 2‐year overall survival SECONDARY OUTCOME: 1‐year overall survival; 1‐year event‐free survival; 2‐year event‐free survival; Overall response rate; Time to treatment failure; Cumulative incidence of infection INCLUSION CRITERIA: Patients previously untreated for AITL
Epistemonikos ID: 1eb7ec5283f97b03095fc716f778c151cfcc3ea9
First added on: Aug 22, 2024